50 related articles for article (PubMed ID: 38685671)
21. Multifunctional inhibitors of SARS-CoV-2 by MM/PBSA, essential dynamics, and molecular dynamic investigations.
Kumar KA; Sharma M; Dalal V; Singh V; Tomar S; Kumar P
J Mol Graph Model; 2021 Sep; 107():107969. PubMed ID: 34237666
[TBL] [Abstract][Full Text] [Related]
22. Flow-cytometric Detection of Low-level Reactive Oxygen Species in Cell Lines and Primary Immune Cells.
Bode K; Link C; Krammer PH; Weyd H
Bio Protoc; 2020 Sep; 10(17):e3737. PubMed ID: 33659398
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial Stress-Mediated Targeting of Quiescent Cancer Stem Cells in Oral Squamous Cell Carcinoma.
Saluja TS; Kumar V; Agrawal M; Tripathi A; Meher RK; Srivastava K; Gupta A; Singh A; Chaturvedi A; Singh SK
Cancer Manag Res; 2020; 12():4519-4530. PubMed ID: 32606945
[TBL] [Abstract][Full Text] [Related]
24. The ORCA quantum chemistry program package.
Neese F; Wennmohs F; Becker U; Riplinger C
J Chem Phys; 2020 Jun; 152(22):224108. PubMed ID: 32534543
[TBL] [Abstract][Full Text] [Related]
25. Computational Prediction of the Mode of Binding of Antitumor Lankacidin C to Tubulin.
Ayoub AT; Elrefaiy MA; Arakawa K
ACS Omega; 2019 Feb; 4(2):4461-4471. PubMed ID: 31459641
[TBL] [Abstract][Full Text] [Related]
26. In silico analysis and molecular dynamics simulation of human superoxide dismutase 3 (SOD3) genetic variants.
Pereira GRC; Da Silva ANR; Do Nascimento SS; De Mesquita JF
J Cell Biochem; 2019 Mar; 120(3):3583-3598. PubMed ID: 30206983
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinone analogues.
El-Azab AS; Abdel-Aziz AA; Ghabbour HA; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):1229-1239. PubMed ID: 28948843
[TBL] [Abstract][Full Text] [Related]
28. Developing force fields when experimental data is sparse: AMBER/GAFF-compatible parameters for inorganic and alkyl oxoanions.
Kashefolgheta S; Vila Verde A
Phys Chem Chem Phys; 2017 Aug; 19(31):20593-20607. PubMed ID: 28731091
[TBL] [Abstract][Full Text] [Related]
29. A computational assessment of pH-dependent differential interaction of T7 lysozyme with T7 RNA polymerase.
Borkotoky S; Murali A
BMC Struct Biol; 2017 May; 17(1):7. PubMed ID: 28545576
[TBL] [Abstract][Full Text] [Related]
30. Measuring Survival of Adherent Cells with the Colony-Forming Assay.
Crowley LC; Christensen ME; Waterhouse NJ
Cold Spring Harb Protoc; 2016 Aug; 2016(8):. PubMed ID: 27480717
[TBL] [Abstract][Full Text] [Related]
31. Clinical experiences with molecular targeted therapy in lung cancer in China.
Wang Y; Sun Y
Thorac Cancer; 2015 Jul; 6(4):379-84. PubMed ID: 26273390
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
33. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
[TBL] [Abstract][Full Text] [Related]
34. Testosterone and benign prostatic hyperplasia.
Jarvis TR; Chughtai B; Kaplan SA
Asian J Androl; 2015; 17(2):212-6. PubMed ID: 25337845
[TBL] [Abstract][Full Text] [Related]
35. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
[TBL] [Abstract][Full Text] [Related]
36. g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations.
Kumari R; Kumar R; ; Lynn A
J Chem Inf Model; 2014 Jul; 54(7):1951-62. PubMed ID: 24850022
[TBL] [Abstract][Full Text] [Related]
37. First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology.
Sebastian M; Schmittel A; Reck M
Eur Respir Rev; 2014 Mar; 23(131):92-105. PubMed ID: 24591666
[TBL] [Abstract][Full Text] [Related]
38. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV; Yang JC; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater SL; Orlov S; Tsai CM; Boyer M; Su WC; Bennouna J; Kato T; Gorbunova V; Lee KH; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M
J Clin Oncol; 2013 Sep; 31(27):3327-34. PubMed ID: 23816960
[TBL] [Abstract][Full Text] [Related]
39. ACPYPE - AnteChamber PYthon Parser interfacE.
Sousa da Silva AW; Vranken WF
BMC Res Notes; 2012 Jul; 5():367. PubMed ID: 22824207
[TBL] [Abstract][Full Text] [Related]
40. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
